Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Lue Shen
- Phone Number: +86 18507159591
- Email: lue.shen@innoventbio.com
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Recruiting
- Westmead Hospital
-
Contact:
- Pei Ding
- Phone Number: 0422 050 656
- Email: pei.ding@health.nsw.gov.au
-
Wollongong, New South Wales, Australia, 2500
- Not yet recruiting
- Wollongong Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Hospital
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230022
- Not yet recruiting
- The First Affiliated Hospital of Anhui Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Not yet recruiting
- The First Affiliated Hospital of Fujian Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Not yet recruiting
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- Hunan Cancer Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Not yet recruiting
- The First Affiliated Hospital of Nanchang University
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Not yet recruiting
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310005
- Recruiting
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
- Male or female subjects ≥ 18 years old. For Part 1, age ≥18 years and ≤75 years;
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
- Minimum life expectancy of ≥ 12 weeks;
- Adequate organ function confirmed at screening period;
- Histologically or cytologically confirmed unresectable,metastatic or Extensive-Stage small cell lung cancer (SCLC).
Exclusion Criteria
- Participating in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of an interventional study;
- Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI CTCAE v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigator's discretion) prior to the first dose of the study drug;
- Known allergies, hypersensitivity, or intolerance to IBI3009 or its excipients;
- Undergone major surgery (Craniotomy, thoracotomy or laparotomy, and other surgery according to investigator's discretion, excluding needle biopsy) within 4 weeks prior to the first dose of the study drug, or who are expected to undergo major surgery during the study period, or who have severe unhealed wounds, trauma, ulcers, etc.;
- Women who are pregnant, have positive results in pregnancy test or are lactating;
- Not eligible to participate in this study at the discretion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IBI3009
|
Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R & D code: IBI3009)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numbers of subjects with adverse events
Time Frame: Up to 3 years
|
defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
|
Up to 3 years
|
|
Number of subjects with clinically significant changes in physical examination results
Time Frame: Up to 3 years
|
Clinically significant abnormal physical examination findings reported by the investigator.
|
Up to 3 years
|
|
Number of subjects with clinically significant changes in electrocardiogram
Time Frame: Up to 3 years
|
Clinically significant abnormal electrocardiogram findings reported by the investigator.
|
Up to 3 years
|
|
Number of subjects with clinically significant changes in vital signs
Time Frame: Up to 3 years
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure
|
Up to 3 years
|
|
Dose limiting toxicities (DLTs)
Time Frame: Up to 28 days
|
Dose limiting toxicities (DLTs) to establish MTD and/or RDE.
|
Up to 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
area under the curve (AUC)
Time Frame: Up to 3 years
|
area under the curve (AUC) of single and multiple doses of IBI3009
|
Up to 3 years
|
|
maximum concentration (Cmax)
Time Frame: Up to 3 years
|
maximum concentration (Cmax) of single and multiple doses of IBI3009
|
Up to 3 years
|
|
time to maximum concentration (Tmax)
Time Frame: Up to 3 years
|
time to maximum concentration (Tmax) of single and multiple doses of IBI3009
|
Up to 3 years
|
|
clearance (CL)
Time Frame: Up to 3 years
|
clearance (CL) of single and multiple doses of IBI3009
|
Up to 3 years
|
|
apparent volume of distribution (V)
Time Frame: Up to 3 years
|
apparent volume of distribution (V) of single and multiple doses of IBI3009
|
Up to 3 years
|
|
half-life (t1/2)
Time Frame: Up to 3 years
|
half-life (t1/2) of IBI3009 to the last administration of IBI3009
|
Up to 3 years
|
|
anti-drug antibody (ADA)
Time Frame: Up to 3 years
|
Incidence and characterization of anti-drug antibody (ADA).
|
Up to 3 years
|
|
objective response rate (ORR)
Time Frame: Up to 3 years
|
objective response rate (ORR) as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
duration of response (DoR)
Time Frame: Up to 3 years
|
duration of response (DoR) as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
time to response (TTR)
Time Frame: Up to 3 years
|
time to response (TTR) as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
progression free survival (PFS)
Time Frame: Up to 3 years
|
as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
overall survival (OS)
Time Frame: Through out the study (an average of 3 years)
|
OS is defined as the time from the date of first dose of study drug until the date of death from any cause.
|
Through out the study (an average of 3 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIBI3009A101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.